NASDAQ:EYEN - Eyenovia Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.78 -0.03 (-1.07 %) (As of 01/20/2019 04:00 PM ET)Previous Close$2.78Today's Range$2.7537 - $2.8852-Week Range$2.40 - $10.74Volume21,657 shsAverage Volume41,219 shsMarket Capitalization$28.05 millionP/E Ratio-1.27Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York. Receive EYEN News and Ratings via Email Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEN Previous Symbol CUSIPN/A Webwww.eyenoviabio.com Phone917-289-1117Debt Debt-to-Equity RatioN/A Current Ratio12.41 Quick Ratio12.41Price-To-Earnings Trailing P/E Ratio-1.27 Forward P/E Ratio-1.70 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book5.45Profitability EPS (Most Recent Fiscal Year)($2.19) Net Income$-5,120,000.00 Net MarginsN/A Return on Equity-70.37% Return on Assets-66.24%Miscellaneous EmployeesN/A Outstanding Shares10,090,000Market Cap$28.05 million OptionableNot Optionable Eyenovia (NASDAQ:EYEN) Frequently Asked Questions What is Eyenovia's stock symbol? Eyenovia trades on the NASDAQ under the ticker symbol "EYEN." How were Eyenovia's earnings last quarter? Eyenovia Inc (NASDAQ:EYEN) posted its earnings results on Tuesday, November, 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.43). View Eyenovia's Earnings History. When is Eyenovia's next earnings date? Eyenovia is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Eyenovia. What price target have analysts set for EYEN? 3 equities research analysts have issued 12-month target prices for Eyenovia's stock. Their predictions range from $12.00 to $35.00. On average, they anticipate Eyenovia's stock price to reach $22.3333 in the next year. This suggests a possible upside of 703.4% from the stock's current price. View Analyst Price Targets for Eyenovia. What is the consensus analysts' recommendation for Eyenovia? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia. What are Wall Street analysts saying about Eyenovia stock? Here are some recent quotes from research analysts about Eyenovia stock: 1. According to Zacks Investment Research, "Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. " (1/18/2019) 2. HC Wainwright analysts commented, "We believe the most important aspect of this conversion is the elimination of special voting rights and protective provisions that were tethered to the Series B preferred shares, eliminating a major pushback by institutional investors who have largely remained on the sidelines. In parallel, a $10M line of credit (LOC) provided by Galectin Chairman Richard E. Uihlein was extended by two years, allowing Galectin to borrow at the prevailing federal rate published by the IRS (now 2.7%) until December 31, 2021 (with repayment due December 31, 2022). While Galectin has yet to tap into this LOC, it nonetheless further extends Galectin’s cash runway which we project to be year end 2019." (1/16/2019) Has Eyenovia been receiving favorable news coverage? News articles about EYEN stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eyenovia earned a media sentiment score of 0.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are some of Eyenovia's key competitors? Some companies that are related to Eyenovia include ASLAN PHARMACEU/ADR (ASLN), Sol Gel Technologies (SLGL), vTv Therapeutics (VTVT), Sierra Oncology (SRRA), Eton Pharmaceuticals (ETON), Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (ZOM), Evofem Biosciences (EVFM), Vernalis (VNLPY), Catalyst Biosciences (CBIO), Avadel Pharmaceuticals (AVDL), DURECT (DRRX), Teligent (TLGT), Generex Biotechnology (GNBT), PhaseBio Pharmaceuticals (PHAS) and BioXcel Therapeutics (BTAI). Who are Eyenovia's key executives? Eyenovia's management team includes the folowing people: Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 44)Ms. Jennifer Clasby, VP of Clinical Operations (Age 64)Mr. Luke Clauson, VP of R&D (Age 39)Mr. John P. Gandolfo, CFO & Sec. (Age 57)Mr. Michael M. Rowe, VP of Marketing When did Eyenovia IPO? (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. How do I buy shares of Eyenovia? Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Eyenovia's stock price today? One share of EYEN stock can currently be purchased for approximately $2.78. How big of a company is Eyenovia? Eyenovia has a market capitalization of $28.05 million. The company earns $-5,120,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. What is Eyenovia's official website? The official website for Eyenovia is http://www.eyenoviabio.com. How can I contact Eyenovia? Eyenovia's mailing address is 501 Fifth Avenue Suite 1404, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected] MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 59 (Vote Outperform)Underperform Votes: 74 (Vote Underperform)Total Votes: 133MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?